Literature DB >> 28273742

N-butyl-2 cyanoacrylate (NBCA) embolus in the graft portal vein after portosystemic collateral embolization in liver transplantation recipient: what is the clinical significance?

Hye Young Jang1,2, Kyoung Won Kim1, Jae Hyun Kwon3, Heon-Ju Kwon4, Bohyun Kim5, Nieun Seo6, Jeongjin Lee7, Gi-Won Song3, Sung-Gyu Lee3.   

Abstract

Background An N-butyl-2 cyanoacrylate (NBCA) embolus in the graft portal vein was frequently observed after an intraoperative embolization of portosystemic collaterals performed to prevent portal steal in liver transplant (LT) recipients. The radiological and clinical features of NBCA emboli have not yet been described. Purpose To describe radiological and clinical features of NBCA embolus in graft portal vein after portosystemic collateral embolization in LT recipients. Material and Methods A total of 165 consecutive LT recipients who had undergone intraoperative NBCA embolization of varix were found in single institution's computerized databases of a clinical cohort of LT. Patients were evaluated for NBCA emboli (categorized into major and minor emboli according to location) on first postoperative computed tomography (CT). All electronic medical records and radiologic studies including follow-up was evaluated to determine any radiological and clinical abnormality associated with NBCA embolus. Results NBCA emboli were found in 24% (39/165) of recipients. Although most patients had minor emboli (77%, 30/39) without remarkable ultrasonography (US) abnormalities, seven (78%) of nine recipients with major emboli showed intraluminal echogenic lesions in graft portal vein on grayscale US, and five of them (71%) showed partial portal flow obstruction, although none exhibited any abnormality on contrast-enhanced US. Recipients with NBCA portal emboli showed no significant clinical abnormalities and were discharged safely. NBCA embolus eventually disappeared mostly within six months (82%, 32/39). Conclusion NBCA emboli are frequently observed after portosystemic collateral embolization in LT recipients and are not associated with poor clinical outcome. They may mimic ordinary thromboemboli on US.

Entities:  

Keywords:  Liver transplantation; N-butyl-2 cyanoacrylate (NBCA); portosystemic shunt; thromboembolism; transplant recipients

Mesh:

Substances:

Year:  2017        PMID: 28273742     DOI: 10.1177/0284185117693460

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  1 in total

1.  Developing protein arginine methyltransferase 1 (PRMT1) inhibitor TC-E-5003 as an antitumor drug using INEI drug delivery systems.

Authors:  Pengcheng Zhang; He Tao; Liyang Yu; Lixiao Zhou; Chenggang Zhu
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.